Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Tamara A Favorito is Director at Artelo Biosciences. OQRO lists 3 transactions filed with the SEC under this name, the latest on Jul 21, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
As of the latest filing on , Tamara A Favorito reported holding 3,894 shares of Zevra Therapeutics (ZVRA), worth about $37K at the last close of $9 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | 3,894 | 3,894 direct | $9 | $37K | Sep 12, 2025 |
Is this Tamara A Favorito’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median +7.8 pts vs S&P 500, beat it 1 of 1 time.
Average +7.8 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Sep 16, 2025 to Sep 16, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 100% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.0 pts (median, against the S&P 500).
Artelo BiosciencesARTL
2 disclosures · Feb 2026 – Jul 2026
Jul 17, 2026136disclosed Jul 21
DetailsOfficial recordJan 30, 2026292disclosed Feb 2
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Sep 12, 2025Bought~$25Kdisclosed Sep 16
DetailsOfficial recordTamara A Favorito bought shares on the open market in 2022, 2023 and 2025.
Tamara A Favorito reported 3 open-market purchases and 0 sales since 2022; purchases in 3 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $25K1×1 trade | — |
| 2023 | $2.5K1×1 trade | — |
| 2022 | $9741×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Sep 12, 2025, Tamara A Favorito reported holding 3,894 shares of Zevra Therapeutics (ZVRA). At the last close of $9 on Nov 17, 2026, that is about $37K. This is the stake disclosed in filings, not a net worth.
Tamara A Favorito bought shares on the open market in 2022, 2023 and 2025.
In SEC filings since 2022: the latest open-market purchase is from 2025; no open-market sale is on record.
Zevra Therapeutics (ZVRA), from 2022 to 2025: 3 purchases and 0 sales.
Tamara A Favorito reported 3 open-market purchases and 0 sales here, 2022 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.